Duration of Effectiveness of the COVID-19 Vaccine in Japan: a Retrospective Cohort Study Using Large-scale Population-based Registry Data

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2024 Jun 29

PMID 38943060

Authors

Kohei Uemura

Sachiko Ono

Nobuaki Michihata

Hayato Yamana

Hideo Yasunaga

Affiliations

Soon will be listed here.

Abstract

Background: Most evidence of the waning of vaccine effectiveness is limited to a relatively short period after vaccination.

Methods: Data obtained from a linked database of healthcare administrative claims and vaccination records maintained by the municipality of a city in the Kanto region of Japan were used in this study. The study period extended from April 1, 2020, to December 31, 2022. The duration of the effectiveness of the COVID-19 vaccine was analyzed using a time-dependent piecewise Cox proportional hazard model using the age, sex and history of cancer, diabetes, chronic obstructive pulmonary disease, asthma, chronic kidney disease, and cardiovascular disease as covariates.

Results: Among the 174,757 eligible individuals, 14,416 (8.3%) were diagnosed with COVID-19 and 936 (0.54%) were hospitalized for COVID-19. Multivariate analysis based on the time-dependent Cox regression model with reference of non-vaccine group revealed a lower incidence of COVID-19 in the one-dose group (hazard ratio, 0.76 [95% confidence interval, 0.63-0.91]), two-dose (0.89 [0.85-0.93]), three-dose (0.80 [0.76-0.85]), four-dose (0.93 [0.88-1.00]), and five-dose (0.72 [0.62-0.84]) groups. A lower incidence of COVID-19-related hospitalization was observed in the one-dose group (0.42 [0.21-0.81]), two-dose (0.44 [0.35-0.56]), three-dose (0.38 [0.30-0.47]), four-dose (0.20 [0.14-0.28]), and five-dose (0.11 [0.014-0.86]) groups. Multivariable analyses based on the time-dependent piecewise Cox proportional hazard model with reference of non-vaccine group revealed significant preventive effects of the vaccine for 4 months for the incidence of COVID-19 and ≥ 6 months for hospitalization.

Conclusions: Vaccine effectiveness showed gradual attenuation with time after vaccination; however, protective effects against the incidence of COVID-19 and hospitalization were maintained for 4 months and ≥ 6 months, respectively. These results may aid in formulating routine vaccination plans after the COVID-19 pandemic.

Citing Articles

Biases in COVID-19 vaccine effectiveness studies using cohort design.

Agampodi S, Tadesse B, Sahastrabuddhe S, Excler J, Kim J Front Med (Lausanne). 2024; 11:1474045.

PMID: 39540039 PMC: 11557388. DOI: 10.3389/fmed.2024.1474045.

References

Thompson M, Natarajan K, Irving S, Rowley E, Griggs E, Gaglani M . Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August.... MMWR Morb Mortal Wkly Rep. 2022; 71(4):139-145. PMC: 9351525. DOI: 10.15585/mmwr.mm7104e3. View

Tartof S, Slezak J, Fischer H, Hong V, Ackerson B, Ranasinghe O . Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021; 398(10309):1407-1416. PMC: 8489881. DOI: 10.1016/S0140-6736(21)02183-8. View

Feikin D, Higdon M, Abu-Raddad L, Andrews N, Araos R, Goldberg Y . Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022; 399(10328):924-944. PMC: 8863502. DOI: 10.1016/S0140-6736(22)00152-0. View

Levin E, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S . Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. N Engl J Med. 2021; 385(24):e84. PMC: 8522797. DOI: 10.1056/NEJMoa2114583. View

Nordstrom P, Ballin M, Nordstrom A . Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. Lancet. 2022; 399(10327):814-823. PMC: 8816388. DOI: 10.1016/S0140-6736(22)00089-7. View

Bar-On Y, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N . Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. N Engl J Med. 2021; 385(15):1393-1400. PMC: 8461568. DOI: 10.1056/NEJMoa2114255. View

Bruxvoort K, Sy L, Qian L, Ackerson B, Luo Y, Lee G . Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study. BMJ. 2021; 375:e068848. PMC: 8671836. DOI: 10.1136/bmj-2021-068848. View

Kobashi Y, Takebayashi Y, Yoshida M, Kawamura T, Shimazu Y, Kaneko Y . Waning of Humoral Immunity and the Influencing Factors after BNT162b2 Vaccination: A Cohort Study with a Latent Growth Curve Model in Fukushima. Vaccines (Basel). 2022; 10(12). PMC: 9782062. DOI: 10.3390/vaccines10122007. View

Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R . Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. N Engl J Med. 2022; 386(4):340-350. PMC: 8781262. DOI: 10.1056/NEJMoa2115481. View

10.

Tang P, Hasan M, Chemaitelly H, Yassine H, Benslimane F, Al Khatib H . BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nat Med. 2021; 27(12):2136-2143. DOI: 10.1038/s41591-021-01583-4. View

11.

da Silva S, Pena L . Collapse of the public health system and the emergence of new variants during the second wave of the COVID-19 pandemic in Brazil. One Health. 2021; 13:100287. PMC: 8240439. DOI: 10.1016/j.onehlt.2021.100287. View

12.

Chemaitelly H, Tang P, Hasan M, Almukdad S, Yassine H, Benslimane F . Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. N Engl J Med. 2021; 385(24):e83. PMC: 8522799. DOI: 10.1056/NEJMoa2114114. View

13.

Ferdinands J, Rao S, Dixon B, Mitchell P, DeSilva M, Irving S . Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. BMJ. 2022; 379:e072141. PMC: 9527398. DOI: 10.1136/bmj-2022-072141. View

14.

Goldberg Y, Mandel M, Bar-On Y, Bodenheimer O, Freedman L, Haas E . Waning Immunity after the BNT162b2 Vaccine in Israel. N Engl J Med. 2021; 385(24):e85. PMC: 8609604. DOI: 10.1056/NEJMoa2114228. View

15.

Chemaitelly H, Yassine H, Benslimane F, Al Khatib H, Tang P, Hasan M . mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med. 2021; 27(9):1614-1621. DOI: 10.1038/s41591-021-01446-y. View

16.

Barda N, Dagan N, Cohen C, Hernan M, Lipsitch M, Kohane I . Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021; 398(10316):2093-2100. PMC: 8555967. DOI: 10.1016/S0140-6736(21)02249-2. View